Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Multiple Myeloma 36Recurrence 9Neoplasms, Plasma Cell 5Neoplasms 3Lymphoma, Non-Hodgkin 2Immunoglobulin Light-chain Amyloidosis 2Hematologic Neoplasms 2Hematologic Diseases 2Blood Protein Disorders 2Thrombocythemia, Essential 1Sarcoma, Kaposi 1Proteostasis Deficiencies 1Primary Myelofibrosis 1Polycythemia Vera 1Paraproteinemias 1Pancreatic Neoplasms 1Neoplasms by Histologic Type 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Primary Effusion 1Leukemia, Myeloid, Acute 1Hypoxia 1Hodgkin Disease 1Corneal Diseases 1Carcinoma, Small Cell 1

Interventions

Cisplatin 4Etoposide 2veliparib 1sagopilone 1sacituzumab govitecan 1pomalidomide 1pembrolizumab 1etoposide phosphate 1Topotecan 1Tomography, X-Ray Computed 1Temozolomide 1Rhenium 1Radiation 1Positron-Emission Tomography 1Podophyllotoxin 1Platinum 1Penfluridol 1Pemetrexed 1PT-100 dipeptide 1Histamine Antagonists 1Epinephrine 1Electrocardiography 1Diphenhydramine 1Dexamethasone 1Calcium Dobesilate 1Acetaminophen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Carcinoma, Small Cell × pomalidomide × Clear all
NCT00537511 2019-11-19

A Phase I/II Study to Determine the Maximum Tolerated Dose (MTD) and Safety of CC-4047 (Pomalidomide) Administered in Conjunction With Cisplatin and Etoposide

Celgene

Phase 1/2 Terminated
22 enrolled 13 charts

Carcinoma, Small Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡